18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
PET (positron emission tomography) scans combined with a radioactive tracer will be used to
identify and analyze tumors. Currently, the most common tracer used to analyze neuroblastoma
tumors is called 123I-mIBG. However, the picture it provides is not always clear enough to
see the very small areas of the disease.
18F-DA (18F-fluorodopamine) has been shown to be safe and more effective than 123I-mIBG in
analyzing the tumor pheochromocytoma, which is closely related to neuroblastoma.
With this research study, the investigators plan to meet the following goals:
- Investigate to see if 18F-DA is safe to administer to pediatric patients with known or
suspected neuroblastoma or pheochromocytoma
- Examine where in the body 18F-DA goes.
- Obtain information comparing 18F-DA to 123I-mIBG to see if 18F-DA could replace
123I-mIBG in the future.
About 20 people, with known or suspected neuroblastoma or pheochromocytoma, will take part in
this Pilot study at St. Jude.